Literature DB >> 9638894

Advances in fibromyalgia: possible role for central neurochemicals.

I J Russell1.   

Abstract

The neurophysiologic term allodynia has been applied to fibromyalgia because people with that disorder experience pain from pressure stimuli which are not normally painful. The nociceptive neurotransmitters of animal studies are now relevant to this human model of chronic, widespread pain. Evidence is presented to implicate several chemical pain mediators (including serotonin, substance P, nerve growth factor, and dynorphin A) in the pathogenesis of fibromyalgia. This perception is hopeful because it offers many new options for the development of innovative therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9638894     DOI: 10.1097/00000441-199806000-00006

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  26 in total

1.  Quantifying pain threshold and quality of life of fibromyalgia patients.

Authors:  A P Marques; E A G Ferreira; L A Matsutani; C A B Pereira; A Assumpção
Journal:  Clin Rheumatol       Date:  2004-12-23       Impact factor: 2.980

Review 2.  Review of overlap between thermoregulation and pain modulation in fibromyalgia.

Authors:  Alice A Larson; José V Pardo; Jeffrey D Pasley
Journal:  Clin J Pain       Date:  2014-06       Impact factor: 3.442

Review 3.  Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders.

Authors:  Lindsay L Kindler; Robert M Bennett; Kim D Jones
Journal:  Pain Manag Nurs       Date:  2009-12-02       Impact factor: 1.929

4.  Influence of catechol-O-methyltransferase (COMT) gene polymorphisms in pain sensibility of Brazilian fibromialgia patients.

Authors:  Flávia Regina Barbosa; Josie Budag Matsuda; Mendelson Mazucato; Suzelei de Castro França; Sônia Marli Zingaretti; Lucienir Maria da Silva; Nilce Maria Martinez-Rossi; Milton Faria Júnior; Mozart Marins; Ana Lúcia Fachin
Journal:  Rheumatol Int       Date:  2010-12-01       Impact factor: 2.631

Review 5.  Psychological determinants of fibromyalgia and related syndromes.

Authors:  J B Winfield
Journal:  Curr Rev Pain       Date:  2000

6.  Action potential simulation (APS) in patients with fibromyalgia syndrome (FMS): a controlled single subject experimental design.

Authors:  R K B Fengler; J W G Jacobs; M Bac; A J M van Wijck; N L U van Meeteren
Journal:  Clin Rheumatol       Date:  2006-05-03       Impact factor: 2.980

7.  Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients.

Authors:  Bernd Frank; Beate Niesler; Brigitta Bondy; Michael Späth; Dieter E Pongratz; Manfred Ackenheil; Christine Fischer; Gudrun Rappold
Journal:  Clin Rheumatol       Date:  2004-05-07       Impact factor: 2.980

8.  Dual allosteric modulation of opioid antinociceptive potency by α2A-adrenoceptors.

Authors:  Anne-Julie Chabot-Doré; Magali Millecamps; Lina Naso; Dominic Devost; Phan Trieu; Marjo Piltonen; Luda Diatchenko; Carolyn A Fairbanks; George L Wilcox; Terence E Hébert; Laura S Stone
Journal:  Neuropharmacology       Date:  2015-08-06       Impact factor: 5.250

Review 9.  Fibromyalgia syndrome in need of effective treatments.

Authors:  Theoharis C Theoharides; Irene Tsilioni; Lauren Arbetman; Smaro Panagiotidou; Julia M Stewart; Rae M Gleason; Irwin J Russell
Journal:  J Pharmacol Exp Ther       Date:  2015-08-25       Impact factor: 4.030

10.  Elevated serum high-sensitivity C-reactive protein levels in fibromyalgia syndrome patients correlate with body mass index, interleukin-6, interleukin-8, erythrocyte sedimentation rate.

Authors:  Yangming Xiao; Wanda L Haynes; Joel E Michalek; I Jon Russell
Journal:  Rheumatol Int       Date:  2012-11-04       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.